Mezzion Pharma Statistics
Total Valuation
Mezzion Pharma has a market cap or net worth of KRW 2.57 trillion. The enterprise value is 2.56 trillion.
| Market Cap | 2.57T |
| Enterprise Value | 2.56T |
Important Dates
The last earnings date was Tuesday, November 11, 2025.
| Earnings Date | Nov 11, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
Mezzion Pharma has 30.36 million shares outstanding. The number of shares has increased by 1.16% in one year.
| Current Share Class | 30.36M |
| Shares Outstanding | 30.36M |
| Shares Change (YoY) | +1.16% |
| Shares Change (QoQ) | +0.06% |
| Owned by Insiders (%) | 9.36% |
| Owned by Institutions (%) | 4.90% |
| Float | 21.97M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 332.26 |
| PB Ratio | 68.95 |
| P/TBV Ratio | 72.07 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -116.84 |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | -226.63 |
Financial Position
The company has a current ratio of 0.88, with a Debt / Equity ratio of 0.29.
| Current Ratio | 0.88 |
| Quick Ratio | 0.60 |
| Debt / Equity | 0.29 |
| Debt / EBITDA | n/a |
| Debt / FCF | -0.97 |
| Interest Coverage | -16.98 |
Financial Efficiency
Return on equity (ROE) is -48.05% and return on invested capital (ROIC) is -18.95%.
| Return on Equity (ROE) | -48.05% |
| Return on Assets (ROA) | -12.10% |
| Return on Invested Capital (ROIC) | -18.95% |
| Return on Capital Employed (ROCE) | -40.77% |
| Revenue Per Employee | 430.53M |
| Profits Per Employee | -1.22B |
| Employee Count | 18 |
| Asset Turnover | 0.10 |
| Inventory Turnover | 1.15 |
Taxes
In the past 12 months, Mezzion Pharma has paid 2.72 billion in taxes.
| Income Tax | 2.72B |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +186.97% in the last 52 weeks. The beta is 0.68, so Mezzion Pharma's price volatility has been lower than the market average.
| Beta (5Y) | 0.68 |
| 52-Week Price Change | +186.97% |
| 50-Day Moving Average | 67,634.00 |
| 200-Day Moving Average | 45,148.50 |
| Relative Strength Index (RSI) | 73.93 |
| Average Volume (20 Days) | 148,299 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Mezzion Pharma had revenue of KRW 7.75 billion and -21.89 billion in losses. Loss per share was -727.38.
| Revenue | 7.75B |
| Gross Profit | 1.51B |
| Operating Income | -15.69B |
| Pretax Income | -19.17B |
| Net Income | -21.89B |
| EBITDA | -14.69B |
| EBIT | -15.69B |
| Loss Per Share | -727.38 |
Balance Sheet
The company has 28.49 billion in cash and 10.93 billion in debt, giving a net cash position of 17.57 billion or 578.55 per share.
| Cash & Cash Equivalents | 28.49B |
| Total Debt | 10.93B |
| Net Cash | 17.57B |
| Net Cash Per Share | 578.55 |
| Equity (Book Value) | 37.35B |
| Book Value Per Share | 1,244.99 |
| Working Capital | -5.89B |
Cash Flow
In the last 12 months, operating cash flow was -11.12 billion and capital expenditures -162.94 million, giving a free cash flow of -11.28 billion.
| Operating Cash Flow | -11.12B |
| Capital Expenditures | -162.94M |
| Free Cash Flow | -11.28B |
| FCF Per Share | -371.62 |
Margins
Gross margin is 19.43%, with operating and profit margins of -202.51% and -282.43%.
| Gross Margin | 19.43% |
| Operating Margin | -202.51% |
| Pretax Margin | -247.31% |
| Profit Margin | -282.43% |
| EBITDA Margin | -189.57% |
| EBIT Margin | -202.51% |
| FCF Margin | n/a |
Dividends & Yields
Mezzion Pharma does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -1.16% |
| Shareholder Yield | -1.16% |
| Earnings Yield | -0.85% |
| FCF Yield | -0.44% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
The last stock split was on April 5, 2022. It was a forward split with a ratio of 3.
| Last Split Date | Apr 5, 2022 |
| Split Type | Forward |
| Split Ratio | 3 |
Scores
Mezzion Pharma has an Altman Z-Score of 9.83 and a Piotroski F-Score of 2.
| Altman Z-Score | 9.83 |
| Piotroski F-Score | 2 |